Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin in T2DM Post Worsening Heart Failure
NCT03521934Phase 3Terminated
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Jun 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) and type 2 diabetes mellitus (T2DM) comparing Sotagliflozin with Placebo (2 arms). Primary endpoint: Total Occurrences of Cardiovascular Death, Hospitalizations for Heart Failure, and Urgent Visits for Heart Failure up to 21.9 months. Started Jun 2018; status: terminated.
02
Drugs
sotagliflozin
03
Conditions
heart failure (HF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03521934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03521934.